Jody Leonard
Primary Care · Annapolis, MDNPI 1679041123
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,596 of the $7,189 with a category attached, or 77.8%. 35 manufacturers reported payments, led by Axonics, Inc. at 30.1% of the total. Among primary care clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 251 payments — averaging $28.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axonics, Inc.$2K
- Sumitomo Pharma America, Inc.$819
- Bayer$540
- Johnson & Johnson$436
- Astellas Pharma US Inc$385
- Ferring Pharmaceuticals Inc.$368
- plus $2K from 29 others
What the payments were for
- Travel & lodging$1,42520%
- Food & beverage$5,59678%
- Education$1682%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axonics, Inc. | 21 | $2,162 |
| Sumitomo Pharma America, Inc. | 36 | $819 |
| Bayer | 21 | $540 |
| Johnson & Johnson | 24 | $436 |
| Astellas Pharma US Inc | 14 | $385 |
| Ferring Pharmaceuticals Inc. | 31 | $368 |
| Urovant Sciences Inc | 13 | $337 |
| Novartis | 13 | $242 |
| Dendreon Pharmaceuticals LLC | 7 | $187 |
| Endo Pharmaceuticals Inc. | 12 | $184 |
| Teleflex LLC | 2 | $150 |
| AbbVie | 6 | $143 |
| Pfizer | 7 | $139 |
| Novo Nordisk | 3 | $134 |
| Accord Healthcare, Inc. | 6 | $128 |
| Tolmar, Inc. | 4 | $101 |
| Coloplast | 1 | $87 |
| Tolmar Pharmaceuticals, Inc. | 3 | $73 |
| Urogen Pharma, Inc. | 3 | $71 |
| Merck | 3 | $69 |
| Philips North America LLC | 1 | $50 |
| AstraZeneca | 2 | $47 |
| Olympus America Inc. | 2 | $41 |
| GSK | 2 | $41 |
| Bioprotect Medical, Inc. | 2 | $39 |
| Myovant Sciences Inc. | 2 | $38 |
| Endo USA, Inc. | 2 | $33 |
| Valencia Technologies Corporation | 1 | $26 |
| Blue Earth Diagnostics | 1 | $21 |
| Progenics Pharmaceuticals, Inc. | 1 | $20 |
| Telix Pharmaceuticals | 1 | $18 |
| Sun Pharmaceutical Industries Inc. | 1 | $17 |
| Vertex | 1 | $16 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $15 |
| Clovis Oncology, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Axonics r-SNM System$1,520
- GEMTESA$208
- UroLift System$133
- RYBELSUS$116
How this compares
$7,189 in reported general payments places this provider in the 95th percentile of 191 primary care providers in Maryland.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 207 | $201,751 |
| MyrbetriqMirabegron | 74 | $70,127 |
| Estradiol | 126 | $9,466 |
| Fosfomycin Tromethamine | 14 | $4,430 |
| Trospium Chloride ErTrospium Chloride | 12 | $2,776 |
| Tamsulosin Hcl | 151 | $2,573 |
| Cephalexin | 80 | $2,247 |
| Methenamine Hippurate | 13 | $1,959 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 13 | $1,843 |
| NitrofurantoinNitrofurantoin Macrocrystal | 43 | $1,561 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 125 | $1,549 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 39 | $1,181 |
| Solifenacin Succinate | 20 | $719 |
| CefuroximeCefuroxime Axetil | 74 | $691 |
| Oxybutynin Chloride ErOxybutynin Chloride | 15 | $425 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $819 | $201,751207 claims |
| Astellas Pharma US IncMyrbetriq | $385 | $70,12774 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 191 primary care providers in Maryland.
Other primary care in Annapolis
- Kristyn LyonsAnnapolis$1K
- Ashley SalamoneBaltimore$13K
- Ololade IkuomolaBaltimore$10K
- Patricia GoodmanUppr Marlboro$8K
- Yury MalachevskyBaltimore$7K
- Kyleen DavisChevy Chase$6K
- Laura Ferguson-WeigmanBel Air$5K
- Roza LissGaithersburg$5K
- Anita Tuli-KendallGaithersburg$5K
- Hannah WhiteheadEssex$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.